Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
Qian Zhou(Jinan University), Liang Chen(Henan Medical University), Zhidong Luan(Qujiang People's Hospital), Yadong Huang(Chongqing University), Qigui Xu(Qujiang People's Hospital), Sujing Yuan(St. Jude Children's Research Hospital), Jinxia Liang(Jinan University), Meng Xu(First Affiliated Hospital of Jinan University), Jin Liu(Sichuan University), Bo Li(Jinan University), Wensheng Chen(Jinan University), Weida Wang(Sun Yat-sen University), Tong Yang(Jinan University), Penghui Zhou(Sun Yat-sen University), Yingchang Li(Jinan University), Zhongjun Xia(Sun Yat-sen University), Zhenzhen Fan(Jinan University)
Cited by 56
Related Papers
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
|Nature Medicine|2008|1.3k
Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation
|Nature Communications|2016|588
Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine
|International Journal of Molecular Sciences|2017|487
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
|Cancer Cell|2006|451
Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity
|Nature Medicine|2019|367